fordadistrogene movaparvovec
Stories
-
Pfizer posts results of Phase 3 gene therapy study in Duchenne Muscular Dystrophy
The study, a Phase 3 long-term safety and efficacy follow-up of fordadistrogene movaparvovec, enrolled 7 participants and was terminated. It began on March 13, 2023, with primary completion on September 24, 2025.